These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 26122697)

  • 1. Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis.
    Jaroszewicz J; Flisiak-Jackiewicz M; Lebensztejn D; Flisiak R
    Expert Opin Investig Drugs; 2015; 24(9):1229-39. PubMed ID: 26122697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline.
    Sanmartín R; Tor J; Sanvisens A; López JJ; Jou A; Muga R; Ojanguren I; Barluenga E; Videla S; Planas R; Clotet B; Tural C
    HIV Med; 2014 Apr; 15(4):203-12. PubMed ID: 24245909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: a decision analysis model.
    Saab S; Hunt DR; Stone MA; McClune A; Tong MJ
    Liver Transpl; 2010 Jun; 16(6):748-59. PubMed ID: 20517909
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers.
    Leeming DJ; Anadol E; Schierwagen R; Karsdal MA; Byrjalsen I; Nielsen MJ; Schwarzer-Zander C; Boesecke C; Bendtsen F; Møller S; Strassburg CP; Spengler U; Krag A; Rockstroh J; Trebicka JK
    AIDS; 2014 Sep; 28(14):2081-90. PubMed ID: 25136933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in the treatment of hepatitis C.
    Lawrence SP
    Adv Intern Med; 2000; 45():65-105. PubMed ID: 10635046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early to Phase II drugs currently under investigation for the treatment of liver fibrosis.
    Hauff P; Gottwald U; Ocker M
    Expert Opin Investig Drugs; 2015 Mar; 24(3):309-27. PubMed ID: 25547844
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibrosing cholestatic hepatitis after successful interferon and ribavirin therapy for recurrent hepatitis C post living related liver transplantation: a case report.
    Yamamoto T; Tanaka S; Uenishi T; Kanazawa A; Kubo S; Hirohashi K
    Osaka City Med J; 2014 Dec; 60(2):95-100. PubMed ID: 25803885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver fibrosis: Direct antifibrotic agents and targeted therapies.
    Schuppan D; Ashfaq-Khan M; Yang AT; Kim YO
    Matrix Biol; 2018 Aug; 68-69():435-451. PubMed ID: 29656147
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progression of liver fibrosis in post-transplant hepatitis C: mechanisms, assessment and treatment.
    Berenguer M; Schuppan D
    J Hepatol; 2013 May; 58(5):1028-41. PubMed ID: 23262248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural history of hepatitis C.
    Westbrook RH; Dusheiko G
    J Hepatol; 2014 Nov; 61(1 Suppl):S58-68. PubMed ID: 25443346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis C and liver fibrosis.
    Schuppan D; Krebs A; Bauer M; Hahn EG
    Cell Death Differ; 2003 Jan; 10 Suppl 1():S59-67. PubMed ID: 12655347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term monitoring of platelet count, as a non-invasive marker of hepatic fibrosis progression and/or regression in patients with chronic hepatitis C after interferon therapy.
    Taniguchi H; Iwasaki Y; Fujiwara A; Sakaguchi K; Moriya A; Yu PC; Takaki A; Fujioka S; Shimomura H; Shiratori Y
    J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):281-7. PubMed ID: 16460487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin blockade does not affect fibrosis progression in recurrent hepatitis C after liver transplantation.
    Guillaud O; Gurram KC; Puglia M; Lilly L; Adeyi O; Renner EL; Selzner N
    Transplant Proc; 2013; 45(6):2331-6. PubMed ID: 23953545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical application of transient elastography in patients with chronic viral hepatitis receiving antiviral treatment.
    Kim JH; Kim MN; Han KH; Kim SU
    Liver Int; 2015 Apr; 35(4):1103-15. PubMed ID: 24976523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab.
    Geri G; Terrier B; Imbert-Bismut F; Saadoun D; Sène D; Poynard T; Cacoub P
    J Viral Hepat; 2012 Jul; 19(7):497-500. PubMed ID: 22676362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approaches for treatment of liver fibrosis in chronic hepatitis C.
    Bedossa P; Paradis V
    Clin Liver Dis; 2003 Feb; 7(1):195-210. PubMed ID: 12691467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Hepatic Fibrosis in Autoimmune Hepatitis.
    Montano-Loza AJ; Thandassery RB; Czaja AJ
    Dig Dis Sci; 2016 Nov; 61(11):3118-3139. PubMed ID: 27435327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.